Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1-2 chronic kidney disease

Nephro-Urology Monthly

Volumn 3, Issue 3, 2011, Pages 164-171

  Hayashi, Kaori ^a   Sasamura, Hiroyuki ^a   Hishiki, Takako ^a   Suematsu, Makoto ^a   Ikeda, Satsuki ^b   Soga, Tomoyoshi ^b   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chronic kidney failure; Mass spectrometry; Metabolomics

Indexed keywords

ADENOSINE; CARNOSINE; GUANINE; HYPOTAURINE; HYPOXANTHINE; TAURINE;

ADULT; ARTICLE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; KIDNEY METABOLISM; MALE; METABOLOME; OXIDATIVE STRESS; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS;

EID: 79959346092     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Szczech LA, Harmon W, Hostetter TH, Klotman PE, Powe NR, Sedor JR, et al. World Kidney Day 2009: problems and challenges in the emerging epidemic of kidney disease. J Am Soc Nephrol. 2009;20(3):453-5.
2. Chamney M, Pugh-Clarke K, Kafkia T. Management of co-morbid diseases in a patient with established renal failure. J Ren Care. 2009;35(3):151-8.
3. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-69.
5. Alvestrand A, Bergstrom J, Furst P, Germanis G, Widstam U. Effect of essential amino acid supplementation on muscle and plasma free amino acids in chronic uremia. Kidney Int. 1978;14(4):323-9.
6. Bergstrom J, Alvestrand A, Furst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int. 1990;38(1):108-14.
7. Canepa A, Filho JC, Gutierrez A, Carrea A, Forsberg AM, Nilsson E, et al. Free amino acids in plasma, red blood cells, polymorphonuclear leukocytes, and muscle in normal and uraemic children. Nephrol Dial Transplant. 2002;17(3):413-21.
8. Furst P. Amino acid metabolism in uremia. J Am Coll Nutr. 1989;8(4):310-23.
9. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis. 2009;19(11):816-24.
10. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of me tabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431-40.
11. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics. 2009;8(3):558-70.
12. Waterman CL, Kian-Kai C, Griffin JL. Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim Biophys Acta. 2010;1801(3):230-4
13. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem. 2006;281(24):16768-76.
14. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-100.
15. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69(11):4918-25.
16. Soga T, Igarashi K, Ito C, Mizobuchi K, Zimmermann HP, Tomita M. Metabolomic Profiling of Anionic Metabolites by Capillary Electrophoresis Mass Spectrometry. Anal Chem. 2009;81:6165-74.
17. Shahbazian H, Zand Moghadam A, Ehsanpour A, Khazaali M. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis. Iran J Kidney Dis. 2009;3(3):151-5.
18. Tarantola M, Motterlini R, Beretta M, Rovida E, Samaja M. Impairment of the post-anoxic recovery of isolated rat hearts by intravascular hypoxanthine and xanthine. Biomater Artif Cells Artif Organs. 1990;18(2):309-20.
19. Oliveira PJ, Rolo AP, Monteiro P, Goncalves L, Palmeira CM, Moreno AJ. Impact of carvedilol on the mitochondrial damage induced by hypoxanthine and xantine oxidase-what role in myocardial ischemia and reperfusion? Rev Port Cardiol. 2002;21(12):1447-55.
20. Ohtsubo T, Matsumura K, Sakagami K, Fujii K, Tsuruya K, Noguchi H, et al. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension. 2009;54(4):868-76.